Global biopharmaceutical company AstraZeneca is strengthening focus on areas such as oncology, cardiovascular, renal, rare diseases, and the emerging GLP-1 segment. In September, it announced its ...

AstraZeneca achieved record revenue growth of 18% in 2024, driven by key products like Farxiga and Tagrisso, and numerous regulatory approvals. The company’s diversified portfolio spans oncology, CVRM ...

VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned ...

VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, ...

The history of pharma and provider partnerships spans back decades, and has traditionally focused on the development of new drugs. Digital is coming into the fold of health, forcing those partnerships ...

China is amid a biotech boom — and increasingly on the radar for US pharma investment as the Asian country moves away from its reputation as a copycat drug producer to a developer of innovative ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.

(Yicai) Sept. 16 -- The China International Import Expo, which opens in just under 50 days, has become not only an important window for multinational drugmakers to showcase global innovation ...

Shares of AstraZeneca (AZN +0.00%) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump. By Eshe Nelson and Liz Alderman Eshe Nelson reported from London, and Liz ...

AstraZeneca announced on Thursday that it plans to invest more than 100 billion yuan ($15 billion) in China by 2030 to expand ...